Santiago Villamayor
Overview
Explore the profile of Santiago Villamayor including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
4
Citations
0
Followers
0
Related Specialty
Related Specialty
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Cosin-Sales J, Sidelnikov E, Villamayor S, Fernandez M, Merino-Montero S, Zamora A
Adv Ther
. 2022 Dec;
40(6):2710-2724.
PMID: 36525203
Introduction: Many patients at very high risk of cardiovascular (CV) events would benefit from lipid-lowering therapies (LLT) intensification to decrease their risk. This study aimed to identify the real-world secondary...
2.
Goicoechea M, Alvarez V, Segarra A, Polaina M, Martin-Reyes G, Robles N, et al.
Nefrologia (Engl Ed)
. 2022 Oct;
42(3):301-310.
PMID: 36210619
Background And Objective: To describe the clinical characteristics, the reasons for initiating therapy and the effects of treatment in the initial phase of evolocumab availability in the Nephrology Units of...
3.
Goicoechea M, Alvarez V, Segarra A, Polaina M, Martin-Reyes G, Robles N, et al.
Nefrologia (Engl Ed)
. 2021 Aug;
PMID: 34389184
Background And Objective: To describe the clinical characteristics, the reasons for initiating therapy and the effects of treatment in the initial phase of evolocumab availability in the Nephrology Units of...
4.
Masana L, Miranda J, Civeira F, Reinares L, Guijarro C, Plana N, et al.
Clin Investig Arterioscler
. 2020 Apr;
32(5):183-192.
PMID: 32317124
Objective: To describe the clinical characteristics, the reasons for initiating therapy, and the effects of treatment in the initial phase of evolocumab availability in lipid/internal medicine units in Spain. Methods:...